share_log

Moderna | 8-K: Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates

Moderna | 8-K: Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates

Moderna | 8-K：Moderna公佈2024年第一季度財務業績並提供業務最新情況
美股sec公告 ·  05/02 06:33
Moomoo AI 已提取核心訊息
On May 2, 2024, Moderna, Inc. reported its financial results for the first quarter ending March 31, 2024, with revenues of $167 million, a significant decrease from $1.9 billion in the same period the previous year. The decline was attributed to reduced sales of its COVID-19 vaccine, Spikevax. Despite a GAAP net loss of $1.2 billion and a diluted EPS of $(3.07), Moderna is preparing for the launches of its RSV vaccine and updated Spikevax formula, with expected product sales of approximately $4 billion for 2024. The company has initiated three new clinical studies in partnership with Merck for cancer treatments and is advancing three new vaccine programs toward Phase 3 clinical trials. Moderna's cash position decreased to $12.2 billion from $13.3 billion at the end of 2023, mainly due to research and development expenses and operating activities. The company reaffirmed its 2024 financial framework, expecting revenue of about $4 billion from its respiratory franchise and projecting year-end cash and investments to be approximately $9 billion.
On May 2, 2024, Moderna, Inc. reported its financial results for the first quarter ending March 31, 2024, with revenues of $167 million, a significant decrease from $1.9 billion in the same period the previous year. The decline was attributed to reduced sales of its COVID-19 vaccine, Spikevax. Despite a GAAP net loss of $1.2 billion and a diluted EPS of $(3.07), Moderna is preparing for the launches of its RSV vaccine and updated Spikevax formula, with expected product sales of approximately $4 billion for 2024. The company has initiated three new clinical studies in partnership with Merck for cancer treatments and is advancing three new vaccine programs toward Phase 3 clinical trials. Moderna's cash position decreased to $12.2 billion from $13.3 billion at the end of 2023, mainly due to research and development expenses and operating activities. The company reaffirmed its 2024 financial framework, expecting revenue of about $4 billion from its respiratory franchise and projecting year-end cash and investments to be approximately $9 billion.
2024年5月2日，Moderna, Inc.公佈了截至2024年3月31日的第一季度財務業績，收入爲1.67億美元，較去年同期的19億美元大幅下降。下降歸因於其 COVID-19 疫苗Spikevax的銷量減少。儘管GAAP淨虧損爲12億美元，攤薄後的每股收益爲3.07美元（3.07美元），但Moderna仍在爲其呼吸道合胞病毒疫苗和更新的Spikevax配方的推出做準備，預計2024年的產品銷售額約爲40億美元。公司已與默沙東合作啓動了三項新的癌症治療臨床研究，並正在推進三項新的疫苗計劃，以進行三期臨床試驗。Moderna的現金狀況從2023年底的133億美元下降至122億美元，這主要是由於研發費用和運營活動所致。該公司重申了其2024年的財務框架，預計其呼吸特許經營權的收入約爲40億美元，並預計年終現金和投資約爲90億美元。
2024年5月2日，Moderna, Inc.公佈了截至2024年3月31日的第一季度財務業績，收入爲1.67億美元，較去年同期的19億美元大幅下降。下降歸因於其 COVID-19 疫苗Spikevax的銷量減少。儘管GAAP淨虧損爲12億美元，攤薄後的每股收益爲3.07美元（3.07美元），但Moderna仍在爲其呼吸道合胞病毒疫苗和更新的Spikevax配方的推出做準備，預計2024年的產品銷售額約爲40億美元。公司已與默沙東合作啓動了三項新的癌症治療臨床研究，並正在推進三項新的疫苗計劃，以進行三期臨床試驗。Moderna的現金狀況從2023年底的133億美元下降至122億美元，這主要是由於研發費用和運營活動所致。該公司重申了其2024年的財務框架，預計其呼吸特許經營權的收入約爲40億美元，並預計年終現金和投資約爲90億美元。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息